Ovarian cancer is a highly aggressive malignancy that primarily spreads within the peritoneal cavity rather than through the bloodstream. Despite its high mortality rate, with only 30% cure rate, it is often diagnosed at an advanced stage, leading to widespread peritoneal metastasis. Ovarian cancer can originate from the ovary, fallopian tube, or mesothelial lining of the peritoneum. It is classified into two main subtypes: type I (low-grade, well-differentiated) and type II (high-grade, aggressive). Type I tumors develop through a stepwise mutation process, while type II tumors are genetically unstable and metastasize rapidly. The initial steps of metastasis involve epithelial-to-mesenchymal transition, allowing cancer cells to detach and attach to the peritoneum. Late metastasis is characterized by rapid tumor growth on mesothelial surfaces, leading to ascites, bowel obstruction, and cachexia. Ovarian cancer cells often undergo an epithelial-to-mesenchymal transition (EMT), which facilitates their detachment and survival in hypoxic conditions. This process involves the loss of E-cadherin and the upregulation of other cadherins, enabling cancer cells to invade and metastasize. The tumor cells can survive in the peritoneal cavity as single cells or spheroids, which are resistant to anoikis and can reattach to the peritoneum. The peritoneal environment, including the mesothelium, plays a critical role in tumor cell adhesion and survival. Ovarian cancer metastasizes primarily to the omentum and peritoneum, with the mesothelium serving as a "soil" for tumor implantation. The metastatic process involves interactions between cancer cells and mesothelial cells, mediated by integrins and adhesion molecules. The tumor cells can also adhere to the peritoneal surface through CD44 and other receptors. The metastatic process is supported by proteolytic activity, including matrix metalloproteinases (MMPs), which facilitate tumor cell detachment and invasion. The genetic basis of ovarian cancer includes mutations in genes such as BRCA1 and BRCA2, as well as alterations in the Ras/Raf/mitogen-activated protein kinase pathway. High-grade serous carcinomas are often associated with p53 mutations and genetic instability. The development of ovarian cancer is influenced by both genetic and epigenetic changes, with type I and type II tumors differing in their molecular pathways and clinical behavior. The treatment of ovarian cancer involves aggressive surgery, including cytoreduction, and chemotherapy. Intraperitoneal chemotherapy has shown improved survival outcomes compared to intravenous administration. The biological behavior of ovarian cancer, confined to the peritoneal cavity, allows for targeted treatment strategies. However, the aggressive nature of the disease and the difficulty in early detection pose significant challenges in treatment. Understanding the molecularOvarian cancer is a highly aggressive malignancy that primarily spreads within the peritoneal cavity rather than through the bloodstream. Despite its high mortality rate, with only 30% cure rate, it is often diagnosed at an advanced stage, leading to widespread peritoneal metastasis. Ovarian cancer can originate from the ovary, fallopian tube, or mesothelial lining of the peritoneum. It is classified into two main subtypes: type I (low-grade, well-differentiated) and type II (high-grade, aggressive). Type I tumors develop through a stepwise mutation process, while type II tumors are genetically unstable and metastasize rapidly. The initial steps of metastasis involve epithelial-to-mesenchymal transition, allowing cancer cells to detach and attach to the peritoneum. Late metastasis is characterized by rapid tumor growth on mesothelial surfaces, leading to ascites, bowel obstruction, and cachexia. Ovarian cancer cells often undergo an epithelial-to-mesenchymal transition (EMT), which facilitates their detachment and survival in hypoxic conditions. This process involves the loss of E-cadherin and the upregulation of other cadherins, enabling cancer cells to invade and metastasize. The tumor cells can survive in the peritoneal cavity as single cells or spheroids, which are resistant to anoikis and can reattach to the peritoneum. The peritoneal environment, including the mesothelium, plays a critical role in tumor cell adhesion and survival. Ovarian cancer metastasizes primarily to the omentum and peritoneum, with the mesothelium serving as a "soil" for tumor implantation. The metastatic process involves interactions between cancer cells and mesothelial cells, mediated by integrins and adhesion molecules. The tumor cells can also adhere to the peritoneal surface through CD44 and other receptors. The metastatic process is supported by proteolytic activity, including matrix metalloproteinases (MMPs), which facilitate tumor cell detachment and invasion. The genetic basis of ovarian cancer includes mutations in genes such as BRCA1 and BRCA2, as well as alterations in the Ras/Raf/mitogen-activated protein kinase pathway. High-grade serous carcinomas are often associated with p53 mutations and genetic instability. The development of ovarian cancer is influenced by both genetic and epigenetic changes, with type I and type II tumors differing in their molecular pathways and clinical behavior. The treatment of ovarian cancer involves aggressive surgery, including cytoreduction, and chemotherapy. Intraperitoneal chemotherapy has shown improved survival outcomes compared to intravenous administration. The biological behavior of ovarian cancer, confined to the peritoneal cavity, allows for targeted treatment strategies. However, the aggressive nature of the disease and the difficulty in early detection pose significant challenges in treatment. Understanding the molecular